Related Experiment Video
Updated: Oct 14, 2025
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
04:12
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
14.7K
Taxane-induced scleroderma. Report of two cases
Jade Cury-Martins1, Laura Giesen2, Sergio González3
1Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
Revista Medica De Chile
|November 9, 2021
Summary
Taxane chemotherapy can cause rare skin conditions like scleroderma. This study reports two breast cancer patients who developed sclerodermic lesions after paclitaxel and nab-paclitaxel treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Taxanes are widely used chemotherapy drugs for various cancers.
- Common side effects include skin hyperpigmentation and hand-foot syndrome.
- Taxane-induced scleroderma is an uncommon but reported adverse event.
Observation:
- Two patients with stage IV breast cancer (aged 66 and 71) were treated with paclitaxel and nab-paclitaxel.
- Both patients developed sclerodermic skin lesions on their extremities.
- These lesions resembled findings seen in systemic sclerosis.
Findings:
- The cases highlight a rare dermatologic adverse event associated with taxane chemotherapy.
- Sclerodermic changes in the extremities were observed following treatment with paclitaxel and nab-paclitaxel.
- This suggests a potential link between these specific taxanes and the development of scleroderma-like skin reactions.
Implications:
- Clinicians should be aware of the possibility of taxane-induced scleroderma.
- Early recognition and management of these skin lesions may be important for patient care.
- Further research is warranted to understand the mechanism and incidence of this rare side effect.
